Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
Background and objective About 80% lung cancer is non-small cell lung cancer (NSCLC) and more than 70% are in advanced stage. The aim of this study is to evaluate the clinical efficacy and the side effects of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-07-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.009&path[]=949 |
| _version_ | 1819055790445559808 |
|---|---|
| author | Haiqing YUAN Yunqi HUA Yongjuan WU Yanxia YANG |
| author_facet | Haiqing YUAN Yunqi HUA Yongjuan WU Yanxia YANG |
| author_sort | Haiqing YUAN |
| collection | DOAJ |
| description | Background and objective About 80% lung cancer is non-small cell lung cancer (NSCLC) and more than 70% are in advanced stage. The aim of this study is to evaluate the clinical efficacy and the side effects of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Twenty-nine patients with advanced non-small cell lung cancer were treated with erlotinib 150 mg/d, then the adverse reaction and clinical efficacy were recorded during 3 months. Results Total 29 patients were evaluated for efficacy. The total rate of effect was 20.69%, including 1 case CR, 5 cases PR, 9 cases SD and 14 cases PD. We compared the effective rate of stage Ⅲ with Ⅳ. There were no significant difference between the effective rate of stage Ⅲand Ⅳ (P=0.337). The main side effects were rash (37.93%), diarrhea (17.24%) and vomiting (6.9%) and most side effects were grade Ⅰand Ⅱ. Conclusion Erlotinib for elderly patients with advanced non-small cell lung cancer have better effective and less toxic effects and the further clinical study should be warranted. |
| first_indexed | 2024-12-21T13:13:07Z |
| format | Article |
| id | doaj.art-715118e9e4024894815a65cbe6d0868d |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-21T13:13:07Z |
| publishDate | 2009-07-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-715118e9e4024894815a65cbe6d0868d2022-12-21T19:02:49ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872009-07-01127789791Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung CancerHaiqing YUANYunqi HUAYongjuan WUYanxia YANGBackground and objective About 80% lung cancer is non-small cell lung cancer (NSCLC) and more than 70% are in advanced stage. The aim of this study is to evaluate the clinical efficacy and the side effects of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Twenty-nine patients with advanced non-small cell lung cancer were treated with erlotinib 150 mg/d, then the adverse reaction and clinical efficacy were recorded during 3 months. Results Total 29 patients were evaluated for efficacy. The total rate of effect was 20.69%, including 1 case CR, 5 cases PR, 9 cases SD and 14 cases PD. We compared the effective rate of stage Ⅲ with Ⅳ. There were no significant difference between the effective rate of stage Ⅲand Ⅳ (P=0.337). The main side effects were rash (37.93%), diarrhea (17.24%) and vomiting (6.9%) and most side effects were grade Ⅰand Ⅱ. Conclusion Erlotinib for elderly patients with advanced non-small cell lung cancer have better effective and less toxic effects and the further clinical study should be warranted.http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.009&path[]=949ErlotinibLung neoplasmsChemotherapy |
| spellingShingle | Haiqing YUAN Yunqi HUA Yongjuan WU Yanxia YANG Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer Chinese Journal of Lung Cancer Erlotinib Lung neoplasms Chemotherapy |
| title | Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| title_full | Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| title_fullStr | Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| title_full_unstemmed | Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| title_short | Clinical Observation of Erlotinib in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| title_sort | clinical observation of erlotinib in the treatment of elderly patients with advanced non small cell lung cancer |
| topic | Erlotinib Lung neoplasms Chemotherapy |
| url | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.07.009&path[]=949 |
| work_keys_str_mv | AT haiqingyuan clinicalobservationoferlotinibinthetreatmentofelderlypatientswithadvancednonsmallcelllungcancer AT yunqihua clinicalobservationoferlotinibinthetreatmentofelderlypatientswithadvancednonsmallcelllungcancer AT yongjuanwu clinicalobservationoferlotinibinthetreatmentofelderlypatientswithadvancednonsmallcelllungcancer AT yanxiayang clinicalobservationoferlotinibinthetreatmentofelderlypatientswithadvancednonsmallcelllungcancer |